An MRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease

Overview

Journal Vaccines (Basel)

Date 2025 Jan 24

PMID 39852831

Authors

Jianglong Li

Haiyan Long

Shaoyi Chen

Zhendong Zhang

Shuang Li

Qi Liu

Jun Liu

Jiaru Cai

Liping Luo

Yucai Peng

Affiliations

Soon will be listed here.

Abstract

Background: Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and the fusion (F) protein is a target for neutralizing antibodies and vaccine development. This study aimed to investigate the immunogenicity and efficacy of an mRNA-based RSV vaccine with an F protein sequence.

Methods: We designed an mRNA construct encoding a modified RSV F protein, which was further developed into an LNP-encapsulated mRNA vaccine (LVRNA007). LVRNA007 was administered to mice and cotton rats, followed by immunogenicity analysis and viral challenge studies. Protection of rodents from the viral infection was evaluated based on the presence of the virus in the lung and pathological examination of respiratory tissues.

Results: LVRNA007 induced robust humoral and cellular immune responses in both mice and cotton rats, with neutralization antibody levels in the immunized animals maintained at high levels for over one year. Vaccination of LVRNA007 also protected the rodents from RSV challenge, judged by the much decreased virus titer and the pathological score in the lung tissue. In addition, no vaccine-enhanced disease (VED) phenomenon was observed with LVRNA007 vaccination.

Conclusions: Based on the preclinical immunogenicity and efficacy data, LVRNA007 could be a potential promising vaccine for prophylaxis of RSV infection.

References

Graham B . Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017; 23:107-112. PMC: 5653266. DOI: 10.1016/j.coviro.2017.03.012. View

Baraldi E, Lisi G, Costantino C, Heinrichs J, Manzoni P, Ricco M . RSV disease in infants and young children: Can we see a brighter future?. Hum Vaccin Immunother. 2022; 18(4):2079322. PMC: 9721445. DOI: 10.1080/21645515.2022.2079322. View

Shaw C, Mithani R, Kapoor A, Dhar R, Wilson L, El Asmar L . Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial. J Infect Dis. 2024; 230(3):e637-e646. PMC: 11420805. DOI: 10.1093/infdis/jiae035. View

Zhang L, Durr E, Galli J, Cosmi S, Cejas P, Luo B . Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability. Vaccine. 2018; 36(52):8119-8130. DOI: 10.1016/j.vaccine.2018.10.032. View

Romagnani S . Lymphokine production by human T cells in disease states. Annu Rev Immunol. 1994; 12:227-57. DOI: 10.1146/annurev.iy.12.040194.001303. View

Karron R, Wright P, Crowe Jr J, Thompson J, Makhene M, Casey R . Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997; 176(6):1428-36. DOI: 10.1086/514138. View

Nussbaum J, Cao X, Railkar R, Sachs J, Spellman D, Luk J . Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine. 2023; 41(44):6488-6501. DOI: 10.1016/j.vaccine.2023.05.062. View

McLellan J, Yang Y, Graham B, Kwong P . Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788-96. PMC: 3147929. DOI: 10.1128/JVI.00555-11. View

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

10.

Xu Z, Wise M, Chokkalingam N, Walker S, Tello-Ruiz E, Elliott S . In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. Adv Sci (Weinh). 2020; 7(8):1902802. PMC: 7175333. DOI: 10.1002/advs.201902802. View

11.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

12.

Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D . Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A. 2012; 109(8):3089-94. PMC: 3286924. DOI: 10.1073/pnas.1115941109. View

13.

Dolgin E . The tangled history of mRNA vaccines. Nature. 2021; 597(7876):318-324. DOI: 10.1038/d41586-021-02483-w. View

14.

Shaw C, Essink B, Harper C, Mithani R, Kapoor A, Dhar R . Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults. J Infect Dis. 2024; 230(3):e647-e656. PMC: 11420773. DOI: 10.1093/infdis/jiae081. View

15.

Kato Y, Abbott R, Freeman B, Haupt S, Groschel B, Silva M . Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. Immunity. 2020; 53(3):548-563.e8. PMC: 7451196. DOI: 10.1016/j.immuni.2020.08.001. View

16.

Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064. PMC: 7613574. DOI: 10.1016/S0140-6736(22)00478-0. View

17.

Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G . Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines. Vaccines (Basel). 2020; 8(4). PMC: 7711987. DOI: 10.3390/vaccines8040672. View

18.

Shan J, Britton P, King C, Booy R . The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. Influenza Other Respir Viruses. 2021; 15(4):539-551. PMC: 8189192. DOI: 10.1111/irv.12850. View

19.

Wright P, Karron R, Madhi S, Treanor J, King J, OShea A . The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006; 193(4):573-81. DOI: 10.1086/499600. View

20.

Richner J, Himansu S, Dowd K, Butler S, Salazar V, Fox J . Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017; 168(6):1114-1125.e10. PMC: 5388441. DOI: 10.1016/j.cell.2017.02.017. View